Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a large randomized, double-blind study

What Was Tested

The paper reports a study of Goserelin in the context of endometriosis, published as a randomized controlled trial.

To confirm the advantages of goserelin prior to endometrial ablation for the treatment of dysfunctional uterine bleeding.

Why It Was Studied

Treatment was timed to allow surgery 6 weeks later on day 7 of the menstrual cycle.

Who Took Part

PubMed indexes the participants as adults, women only.

Cycling premenopausal women with dysfunctional uterine bleeding.

Patients were randomized to goserelin or placebo (sham depot) once monthly for 2 months prior to endometrial ablation.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Goserelin and who got the comparison, which limits bias.

As a double-blind Goserelin study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Goserelin group a baseline to be compared against.

More than one site took part, so the participants came from several places.

The timeline in the abstract includes 2 months.

Multicenter, prospective, randomized, double-blind study.

What Was Measured

Topics PubMed links to this paper include Antineoplastic Agents, Hormonal, Endometrium, Goserelin, Hysteroscopy, Ultrasonography and Uterine Hemorrhage.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Goserelin in people with endometriosis over 2 months.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1997 (Fertility and sterility), a journal based in United States.

More context: the Goserelin compound page, Endometriosis research.